What is a key feature of Apligraf in the treatment of venous ulcers?

Apligraf is indeed the only FDA-approved bioengineered skin substitute specifically for the treatment of diabetic and venous ulcers. This unique designation underscores its significance in managing chronic wounds that result from circulatory issues, such as venous insufficiency. Apligraf is composed of human-derived cells, which include keratinocytes and fibroblasts embedded in a collagen matrix, allowing it to promote healing by mimicking the natural structure and function of human skin.

The available options relate to other aspects of skin treatments but do not accurately describe Apligraf's specific status and application. Apligraf’s FDA approval highlights its clinical efficacy and safety profile, which has been substantiated by various studies showing its effectiveness in enhancing healing rates in venous and diabetic ulcers. Thus, its uniqueness in the treatment landscape for these types of ulcers makes this answer particularly relevant for individuals studying wound care or pursuing certification in phlebology.